April 04, 2025

First IgG4-RD Treatment Approved

A humanized monoclonal antibody that targets CD19+ B cells is first FDA-approved treatment for immunoglobulin G4–related disease, reducing flare risk and glucocorticoid use in clinical trials.

Conexiant

April 03, 2025

New Option for IgA Nephropathy Management

The FDA has granted accelerated approval to Vanrafia (atrasentan) for reducing proteinuria in adults with primary immunoglobulin A nephropathy who are at risk of rapid disease progression.

Conexiant

April 02, 2025

HPV Testing Guidelines Updated for Head and Neck Carcinomas

New evidence expands recommendations for sinonasal squamous cell carcinoma and standardizes p16 immunohistochemistry interpretation.

Conexiant

April 01, 2025

Cemiplimab Effective for Advanced cSCC

Meta-analysis of 19 studies reveals promising 54.5% objective response rate and manageable safety profile for PD-1 inhibitor in treating advanced cutaneous squamous cell carcinoma.

Conexiant

March 27, 2025

Randomized Trial Evaluates ICG Fluorescence in Surgical Outcomes

Routine use of ICG fluorescence imaging does not significantly reduce anastomotic leak rates in colorectal surgery, though a potential benefit was observed for left-sided operations.

Conexiant

February 05, 2025

Enlarging Painless Nodule Destroying Nail: What's Your Diagnosis?

A painless finger nodule leads to nail destruction, revealing an uncommon but locally aggressive tumor of the tendon sheath.

Conexiant

March 07, 2025

What's Your Diagnosis? Persistent Sore Throat and Lymphadenopathy in a 67-Year-Old Man

A 67-year-old man's secondary syphilis was diagnosed nearly a year after presenting with persistent sore throat and swollen lymph nodes.

Conexiant

January 15, 2025

Achalasia: Candida's Role in Cancer Risk

New study links esophageal Candida infection to significant cancer risk increase in achalasia patients.

Conexiant

January 22, 2025

Thyroidectomy IONM: Usage Up, Benefits Modest

"Although IONM during thyroidectomy is common in the US, these results suggest that further research is needed to identify patients who would benefit the most from this technology."

Conexiant